KEBI-Cyto Study - Use of the Biocartis Idylla

Plain-language summary

This study evaluates the use of the Biocartis Idylla real-time PCR platform, which detects EGFR, KRAS, and BRAF mutations in liquid-based cytology and blood plasma samples. It enrolled patients over 18 diagnosed with non-small cell lung carcinoma or pancreatic adenocarcinoma. It was a study without an assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Royal Cornwall Hospitals Trust

Intervention

Biocartis Idylla platform - real time PCR detecting EGFR, KRAS and BRAF mutations in liquid based cytology and blood plasma samples

Start date

7/7/2020

Estimated completion

3/7/2022

Countries

United Kingdom

Related genes

Locations

• Truro, United Kingdom

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Cytological / histological diagnosis of non small cell lung carcinoma or pancreatic adenocarcinoma
* Patients of any gender ethnicity or socioeconomic grouping
* Patients over the age of 18 years

Exclusion Criteria:

* Other malignancies (Not non small cell lung carcinoma or pancreatic adenocarcinoma)
* Benign diagnosis
* Patients under the age of 18